• 1
    Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007; 117: 55767.
  • 2
    Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med 2009; 360: 19892003.
  • 3
    Manetti M, Guiducci S, Ibba-Manneschi L, Matucci-Cerinic M. Mechanisms in the loss of capillaries in systemic sclerosis: angiogenesis versus vasculogenesis. J Cell Mol Med 2010; 14: 124154.
  • 4
    Chizzolini C. T cells, B cells, and polarized immune response in the pathogenesis of fibrosis and systemic sclerosis. Curr Opin Rheumatol 2008; 20: 70712.
  • 5
    Roumm AD, Whiteside TL, Medsger TA Jr, Rodnan GP. Lymphocytes in the skin of patients with progressive systemic sclerosis: quantification, subtyping, and clinical correlations. Arthritis Rheum 1984; 27: 64553.
  • 6
    Kraling BM, Maul GG, Jimenez SA. Mononuclear cell infiltrates in clinically involved skin from patients with systemic sclerosis of recent onset predominantly consist of monocytes/macrophages. Pathobiology 1995; 63: 4856.
  • 7
    Scharffetter K, Lankat-Buttgereit B, Krieg T. Localization of collagen mRNA in normal and scleroderma skin by in-situ hybridization. Eur J Clin Invest 1988; 18: 917.
  • 8
    Sato S. Abnormalities of adhesion molecules and chemokines in scleroderma. Curr Opin Rheumatol 1999; 11: 5037.
  • 9
    Koch AE, Kronfeld-Harrington LB, Szekanecz Z, Cho MM, Haines GK, Harlow LA, et al. In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis: their role in early and late disease. Pathobiology 1993; 61: 23946.
  • 10
    Sollberg S, Peltonen J, Uitto J, Jimenez SA. Elevated expression of β1 and β2 integrins, intercellular adhesion molecule 1, and endothelial leukocyte adhesion molecule 1 in the skin of patients with systemic sclerosis of recent onset. Arthritis Rheum 1992; 35: 2908.
  • 11
    Rabquer BJ, Hou Y, Del Galdo F, Haines GK III, Gerber ML, Jimenez SA, et al. The proadhesive phenotype of systemic sclerosis skin promotes myeloid cell adhesion via ICAM-1 and VCAM-1. Rheumatology (Oxford) 2009; 48: 73440.
  • 12
    Manetti M, Neumann E, Muller A, Schmeiser T, Saar P, Milia AF, et al. Endothelial/lymphocyte activation leads to prominent CD4+ T cell infiltration in the gastric mucosa of patients with systemic sclerosis. Arthritis Rheum 2008; 58: 286673.
  • 13
    Abraham D, Lupoli S, McWhirter A, Plater-Zyberk C, Piela TH, Korn JH, et al. Expression and function of surface antigens on scleroderma fibroblasts. Arthritis Rheum 1991; 34: 116472.
  • 14
    Polverini PJ. Cellular adhesion molecules: newly identified mediators of angiogenesis. Am J Pathol 1996; 148: 10239.
  • 15
    Kuryliszyn-Moskal A, Klimiuk PA, Sierakowski S. Soluble adhesion molecules (sVCAM-1, sE-selectin), vascular endothelial growth factor (VEGF) and endothelin-1 in patients with systemic sclerosis: relationship to organ systemic involvement. Clin Rheumatol 2005; 24: 1116.
  • 16
    Kiener H, Graninger W, Machold K, Aringer M, Graninger WB. Increased levels of circulating intercellular adhesion molecule-1 in patients with systemic sclerosis. Clin Exp Rheumatol 1994; 12: 4837.
  • 17
    Denton CP, Bickerstaff MC, Shiwen X, Carulli MT, Haskard DO, Dubois RM, et al. Serial circulating adhesion molecule levels reflect disease severity in systemic sclerosis. Br J Rheumatol 1995; 34: 104854.
  • 18
    Weber C, Fraemohs L, Dejana E. The role of junctional adhesion molecules in vascular inflammation. Nat Rev Immunol 2007; 7: 46777.
  • 19
    Bazzoni G. Pathobiology of junctional adhesion molecules. Antioxid Redox Signal 2011; 15: 122134.
  • 20
    Ong KL, Leung RY, Babinska A, Salifu MO, Ehrlich YH, Kornecki E, et al. Elevated plasma level of soluble F11 receptor/junctional adhesion molecule-A (F11R/JAM-A) in hypertension. Am J Hypertens 2009; 22: 5005.
  • 21
    Vetrano S, Rescigno M, Cera MR, Correale C, Rumio C, Doni A, et al. Unique role of junctional adhesion molecule-A in maintaining mucosal homeostasis in inflammatory bowel disease. Gastroenterology 2008; 135: 17384.
  • 22
    Rabquer BJ, Pakozdi A, Michel JE, Gujar BS, Haines GK III, Imhof BA, et al. Junctional adhesion molecule C mediates leukocyte adhesion to rheumatoid arthritis synovium. Arthritis Rheum 2008; 58: 30209.
  • 23
    LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 2025.
  • 24
    Medsger TA Jr, Steen VD. Classification, prognosis. In: Clements PJ, Furst DE, eds. Systemic sclerosis. 2nd ed. Philadelphia: Lippincott Williams & Wilkins 1996: 5179.
  • 25
    Manetti M, Guiducci S, Romano E, Bellando-Randone S, Conforti ML, Ibba-Manneschi L, et al. Increased serum levels and tissue expression of matrix metalloproteinase-12 in patients with systemic sclerosis: correlation with severity of skin and pulmonary fibrosis and vascular damage. Ann Rheum Dis 2012; 71: 106472.
  • 26
    Scott PA, Bicknell R. The isolation and culture of microvascular endothelium. J Cell Sci 1993; 105: 26973.
  • 27
    Manetti M, Guiducci S, Romano E, Ceccarelli C, Bellando-Randone S, Conforti ML, et al. Overexpression of VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, leads to insufficient angiogenesis in patients with systemic sclerosis. Circ Res 2011; 109: e1426.
  • 28
    Naik MU, Mousa SA, Parkos CA, Naik UP. Signaling through JAM-1 and αvβ3 is required for the angiogenic action of bFGF: dissociation of the JAM-1 and αvβ3 complex. Blood 2003; 102: 210814.
  • 29
    Orlova VV, Economopoulou M, Lupu F, Santoso S, Chavakis T. Junctional adhesion molecule-C regulates vascular endothelial permeability by modulating VE-cadherin–mediated cell–cell contacts. J Exp Med 2006; 203: 270314.
  • 30
    Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 2007; 7: 67889.
  • 31
    Muller WA. Leukocyte-endothelial-cell interactions in leukocyte transmigration and the inflammatory response. Trends Immunol 2003; 24: 32734.
  • 32
    Bradfield PF, Nourshargh S, Aurrand-Lions M, Hop W, Verkaik AP, Hilvering C. JAM family and related proteins in leukocyte migration. Arterioscler Thromb Vasc Biol 2007; 27: 210412.
  • 33
    Scheiermann C, Colom B, Meda P, Patel NS, Voisin MB, Marrelli A, et al. Junctional adhesion molecule-C mediates leukocyte infiltration in response to ischemia reperfusion injury. Arterioscler Thromb Vasc Biol 2009; 29: 150915.
  • 34
    Martin-Padura I, Lostaglio S, Schneemann M, Williams L, Romano M, Fruscella P, et al. Junctional adhesion molecule, a novel member of the immunoglobulin superfamily that distributes at intercellular junctions and modulates monocyte transmigration. J Cell Biol 1998; 142: 11727.
  • 35
    Ludwig RJ, Zollner TM, Santoso S, Hardt K, Gille J, Baatz H, et al. Junctional adhesion molecules (JAM)-B and -C contribute to leukocyte extravasation to the skin and mediate cutaneous inflammation. J Invest Dermatol 2005; 125: 96976.
  • 36
    Hou Y, Rabquer BJ, Gerber ML, Del Galdo F, Jimenez SA, Haines GK III, et al. Junctional adhesion molecule-A is abnormally expressed in diffuse cutaneous systemic sclerosis skin and mediates myeloid cell adhesion. Ann Rheum Dis 2010; 69: 24954.
  • 37
    Rudnicka L, Majewski S, Blaszczyk M, Skiendzielewska A, Makiela B, Skopinska M, et al. Adhesion of peripheral blood mononuclear cells to vascular endothelium in patients with systemic sclerosis (scleroderma). Arthritis Rheum 1992; 35: 7715.
  • 38
    Stummvoll GH, Aringer M, Grisar J, Steiner CW, Smolen JS, Knobler R, et al. Increased transendothelial migration of scleroderma lymphocytes. Ann Rheum Dis 2004; 63: 56974.
  • 39
    Aden N, Shiwen X, Aden D, Black C, Nuttall A, Denton CP, et al. Proteomic analysis of scleroderma lesional skin reveals activated wound healing phenotype of epidermal cell layer. Rheumatology (Oxford) 2008; 47: 175460.
  • 40
    Dees C, Akhmetshina A, Zerr P, Reich N, Palumbo K, Horn A, et al. Platelet-derived serotonin links vascular disease and tissue fibrosis. J Exp Med 2011; 208: 96172.
  • 41
    Cooke VG, Naik MU, Naik UP. Fibroblast growth factor-2 failed to induce angiogenesis in junctional adhesion molecule-deficient mice. Arterioscler Thromb Vasc Biol 2006; 26: 200511.
  • 42
    Lamagna C, Hodivala-Dilke KM, Imhof BA, Aurrand-Lions M. Antibody against junctional adhesion molecule-C inhibits angiogenesis and tumor growth. Cancer Res 2005; 65: 570310.
  • 43
    Cavusoglu E, Kornecki E, Sobocka MB, Babinska A, Ehrlich YH, Chopra V, et al. Association of plasma levels of F11 receptor/junctional adhesion molecule-A (F11R/JAM-A) with human atherosclerosis. J Am Coll Cardiol 2007; 50: 176876.
  • 44
    Rabquer BJ, Amin MA, Teegala N, Shaheen MK, Tsou PS, Ruth JH, et al. Junctional adhesion molecule-C is a soluble mediator of angiogenesis. J Immunol 2010; 185: 177785.